Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Antibody-mediated clearance of tau in primary mouse microglial cultures requires Fcγ-receptor binding and functional lysosomes.

Andersson CR, Falsig J, Stavenhagen JB, Christensen S, Kartberg F, Rosenqvist N, Finsen B, Pedersen JT.

Sci Rep. 2019 Mar 15;9(1):4658. doi: 10.1038/s41598-019-41105-4.

2.

Highly specific and selective anti-pS396-tau antibody C10.2 targets seeding-competent tau.

Rosenqvist N, Asuni AA, Andersson CR, Christensen S, Daechsel JA, Egebjerg J, Falsig J, Helboe L, Jul P, Kartberg F, Pedersen LØ, Sigurdsson EM, Sotty F, Skjødt K, Stavenhagen JB, Volbracht C, Pedersen JT.

Alzheimers Dement (N Y). 2018 Oct 14;4:521-534. doi: 10.1016/j.trci.2018.09.005. eCollection 2018.

3.

Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration.

Ryu JK, Rafalski VA, Meyer-Franke A, Adams RA, Poda SB, Rios Coronado PE, Pedersen LØ, Menon V, Baeten KM, Sikorski SL, Bedard C, Hanspers K, Bardehle S, Mendiola AS, Davalos D, Machado MR, Chan JP, Plastira I, Petersen MA, Pfaff SJ, Ang KK, Hallenbeck KK, Syme C, Hakozaki H, Ellisman MH, Swanson RA, Zamvil SS, Arkin MR, Zorn SH, Pico AR, Mucke L, Freedman SB, Stavenhagen JB, Nelson RB, Akassoglou K.

Nat Immunol. 2018 Nov;19(11):1212-1223. doi: 10.1038/s41590-018-0232-x. Epub 2018 Oct 15.

4.

Development of a Cell-Based Assay to Assess Binding of the proNGF Prodomain to Sortilin.

Malik I, Christensen S, Stavenhagen JB, Dietz GPH.

Cell Mol Neurobiol. 2018 May;38(4):827-840. doi: 10.1007/s10571-017-0558-1. Epub 2017 Oct 24.

5.

Comparing the efficacy and neuroinflammatory potential of three anti-abeta antibodies.

Fuller JP, Stavenhagen JB, Christensen S, Kartberg F, Glennie MJ, Teeling JL.

Acta Neuropathol. 2015 Nov;130(5):699-711. doi: 10.1007/s00401-015-1484-2. Epub 2015 Oct 3.

6.

New roles for Fc receptors in neurodegeneration-the impact on Immunotherapy for Alzheimer's Disease.

Fuller JP, Stavenhagen JB, Teeling JL.

Front Neurosci. 2014 Aug 21;8:235. doi: 10.3389/fnins.2014.00235. eCollection 2014. Review.

7.

The identification of AF38469: an orally bioavailable inhibitor of the VPS10P family sorting receptor Sortilin.

Schrøder TJ, Christensen S, Lindberg S, Langgård M, David L, Maltas PJ, Eskildsen J, Jacobsen J, Tagmose L, Simonsen KB, Biilmann Rønn LC, de Jong IE, Malik IJ, Karlsson JJ, Bundgaard C, Egebjerg J, Stavenhagen JB, Strandbygård D, Thirup S, Andersen JL, Uppalanchi S, Pervaram S, Kasturi SP, Eradi P, Sakumudi DR, Watson SP.

Bioorg Med Chem Lett. 2014 Jan 1;24(1):177-80. doi: 10.1016/j.bmcl.2013.11.046. Epub 2013 Nov 27.

PMID:
24355129
8.

Enhancing the potency of therapeutic monoclonal antibodies via Fc optimization.

Stavenhagen JB, Gorlatov S, Tuaillon N, Rankin CT, Li H, Burke S, Huang L, Johnson S, Koenig S, Bonvini E.

Adv Enzyme Regul. 2008;48:152-64. doi: 10.1016/j.advenzreg.2007.11.011. Epub 2007 Dec 3. No abstract available.

PMID:
18177741
9.

Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.

Stavenhagen JB, Gorlatov S, Tuaillon N, Rankin CT, Li H, Burke S, Huang L, Vijh S, Johnson S, Bonvini E, Koenig S.

Cancer Res. 2007 Sep 15;67(18):8882-90. Erratum in: Cancer Res. 2008 Sep 15;68(18):7692. Vijh, Sujata [added].

10.
11.

Stability of a CTG/CAG trinucleotide repeat in yeast is dependent on its orientation in the genome.

Freudenreich CH, Stavenhagen JB, Zakian VA.

Mol Cell Biol. 1997 Apr;17(4):2090-8.

12.

Internal tracts of telomeric DNA act as silencers in Saccharomyces cerevisiae.

Stavenhagen JB, Zakian VA.

Genes Dev. 1994 Jun 15;8(12):1411-22.

13.
14.

Isolation and characterization of the RNA2, RNA3, and RNA11 genes of Saccharomyces cerevisiae.

Last RL, Stavenhagen JB, Woolford JL Jr.

Mol Cell Biol. 1984 Nov;4(11):2396-405.

Supplemental Content

Loading ...
Support Center